BMO Capital Markets Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price objective raised by stock analysts at BMO Capital Markets from $142.00 to $170.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 12.49% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research report on Wednesday, August 12th. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Finally, Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $142.10.

Merck & Co., Inc. Stock Down 0.7%

Shares of NYSE MRK traded down $1.07 during mid-day trading on Thursday, hitting $151.13. The company had a trading volume of 7,921,023 shares, compared to its average volume of 10,777,994. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a 50-day simple moving average of $126.86 and a two-hundred day simple moving average of $120.74. The company has a market capitalization of $372.86 billion, a PE ratio of 120.90, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $153.50.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the company earned $2.13 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last ninety days. Insiders own 0.17% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Several institutional investors have recently modified their holdings of MRK. Vanguard Group Inc. increased its position in Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. BlackRock Inc. increased its holdings in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp lifted its stake in Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after buying an additional 1,859,990 shares during the period. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after buying an additional 11,156,354 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after buying an additional 249,110 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Landmark cancer-vaccine trial success: Merck and Moderna reported that their personalized mRNA therapy, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a Phase 3 melanoma study. The treatment improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in high-risk patients. The result could expand Keytruda’s commercial opportunity and create a new growth avenue as its patent expiration approaches later this decade. Reuters trial report
• Positive Sentiment: Analyst upgrades and higher targets: Morgan Stanley upgraded MRK to “overweight” with a $179 price target, while UBS raised its target to $175 and initiated a “buy” rating. The targets imply continued upside and indicate that analysts view the melanoma results as strategically important for Merck’s oncology pipeline. Analyst ratings report
• Positive Sentiment: Potentially broader pipeline value: The first positive late-stage validation of a personalized mRNA cancer vaccine has strengthened expectations that similar Merck-Moderna programs could target additional cancers, supporting longer-term pipeline diversification beyond Keytruda. Reuters cancer-vaccine analysis
• Neutral Sentiment: Mixed Wall Street signals: RBC raised its price target to $150 but maintained a “sector perform” rating, while Jefferies downgraded Merck from “strong buy” to “hold.” This suggests some analysts believe the recent gains already reflect much of the positive news. Analyst ratings report
• Negative Sentiment: Profit-taking and data limitations: Moderna’s shares have retreated after an exceptionally large rally, and Merck has also eased from its highs. Investors are awaiting detailed Phase 3 data and regulatory filings; approval, commercial adoption and the economics of the partnership remain uncertain.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.